Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intentXx_NEWLINE_xXCurrent participation in another therapeutic clinical trialXx_NEWLINE_xXThe patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.Xx_NEWLINE_xXCurrent treatment or participation on another therapeutic clinical trialXx_NEWLINE_xXNot participating in another weight loss, physical activity or dietary intervention clinical trial; co-enrollment in some trials involving pharmacologic therapy is allowed; participants in both arms are also allowed to pursue weight loss and physical activity programs on their own, as long as these programs are not provided as part of a clinical trialXx_NEWLINE_xXConcurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin useXx_NEWLINE_xXPatients currently enrolled in other clinical trials testing a therapeutic interventionXx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the 21 days prior to first dose of olaparib and temozolomideXx_NEWLINE_xXConcurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)Xx_NEWLINE_xXConcurrent enrollment in another clinical study, unless in follow-up period or it is an observational studyXx_NEWLINE_xXConcurrent participation in another therapeutic clinical trialXx_NEWLINE_xXInvestigational agents from previous clinical study within 4 weeksXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study;Xx_NEWLINE_xXConcurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowedXx_NEWLINE_xXPatients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigatorXx_NEWLINE_xXParticipation in another therapeutic clinical study or receiving any investigational agent within 28 days of enrollment or during this clinical studyXx_NEWLINE_xXConcurrent enrollment in another therapeutic clinical trial.Xx_NEWLINE_xXCurrent participation in another clinical trial of a drug or device or past participation within 4 weeks before Baseline or subject is in exclusion period from a previous clinical trialXx_NEWLINE_xXSubjects currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drugXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intentXx_NEWLINE_xXConcurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXPatients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigatorXx_NEWLINE_xXParticipation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;Xx_NEWLINE_xXParticipation in any other clinical trial within 4 weeks prior to randomization.Xx_NEWLINE_xXParticipation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e. D1 of cycle 1)Xx_NEWLINE_xXPatients being treated with any other experimental agents/clinical trials are not eligible for participation; if the patient is on any investigational agent, a wash-out period of minimum 2 weeks prior to registration is mandatory for the patient to be eligible for the studyXx_NEWLINE_xXParticipation in a clinical trial in which the patient received an investigational drug or device must be discontinued at enrollment.Xx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients are candidates for chemotherapy with carboplatin and gemcitabineXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients participating in another trial of an investigational agent within 4 weeks of the first dose of the studyXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients with tumors that cannot be measured or clinically followed (i.e. evaluable disease)Xx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients known to be carriers of human immunodeficiency virus (HIV1/2)Xx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients known to be carriers of hepatitis virus B and CXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Subjects who do not consent to providing pre and post treatment tissue sample for future research would not be eligible to participate in the trialXx_NEWLINE_xXHave participated in another therapeutic clinical trial with an investigational drug within 1 monthXx_NEWLINE_xXNo concurrent treatment on another clinical trial; supportive care trials or nontreatment trials, e.g. quality of life, are allowedXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to Day 1 of the study.Xx_NEWLINE_xXPatients who are participating in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of registration and throughout the duration of this trial are not eligibleXx_NEWLINE_xXPrior participation in a clinical study of viagenpumatucel-LXx_NEWLINE_xXBone marrow reserve which, in the clinical judgment of the Principal Investigator, is not adequate for participation in this trial.Xx_NEWLINE_xXParticipated in a therapeutic clinical study within 3 weeks before study drug treatment, or current participation in other therapeutic investigational procedures.Xx_NEWLINE_xXParticipation in any clinical trial, within four weeks prior to registration on this trial, which involved an investigational drug or deviceXx_NEWLINE_xXAre currently enrolled in, or have discontinued within 30 days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device.Xx_NEWLINE_xXLogistical or psychological hindrance to participation in clinical researchXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in other therapeutic clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXFor more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.comXx_NEWLINE_xXRequiring treatment with any of the prohibited concomitant medications listed that cannot be stopped for the duration of trial participationXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.Xx_NEWLINE_xXEnrolled in another clinical trial testing a novel therapy or drug within the past 4 weeks.Xx_NEWLINE_xXPrevious participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participationXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug prior to enrollmentXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.Xx_NEWLINE_xXThe patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.Xx_NEWLINE_xXConcurrent enrollment in another interventional trialXx_NEWLINE_xXIs participating in another therapeutic clinical trialXx_NEWLINE_xXLogistical or psychological hindrance to participation in clinical researchXx_NEWLINE_xXNegative pregnancy test within 72 hours prior to the first dose of protocol therapy for women of childbearing potential. Must be willing to use effective contraception for 30 days before the first study drug administration, for the duration of trial participation and at least for 60 days after stopping trial participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician must be informed immediately.Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXIs currently receiving tazemetostat as either monotherapy or in combination with other approved drug(s) or investigational agent(s) on an Epizyme-sponsored clinical trial or any other clinical trial being conducted with tazemetostat that is not sponsored by Epizyme (including but not limited to, Investigator initiated trials). For subjects on combination therapy, the other therapeutic(s) must have been completed or will be provided by a source other than EpizymeXx_NEWLINE_xXCurrent active treatment in another clinical study.Xx_NEWLINE_xXHave participated, within the last 28 days in a clinical trial involving an investigational product or are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.Xx_NEWLINE_xXParticipant in other clinical trialsXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, such as monoclonal antibodies, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 30 daysXx_NEWLINE_xXAny investigational agents or drugs from a previous clinical study within 28 daysXx_NEWLINE_xXEnrollment into another therapeutic clinical trial.Xx_NEWLINE_xXConcurrent participation in other investigational drug trials.Xx_NEWLINE_xXReceipt of therapy on a clinical trial, including investigational and non-investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial; participation on non-therapeutic clinical studies is allowed, and patients who participated on a clinical trial for induction and/or transplant but who have completed the prescribed therapy course for that study and have been off therapy for at least 30 days are eligibleXx_NEWLINE_xXRequiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participationXx_NEWLINE_xXParticipation in other clinical treatment trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXClinical diagnosis of one of the following:Xx_NEWLINE_xXAny concurrent medications which could interfere with the trialXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agentXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21days of the start of this trial and throughout induction and consolidation 1 portions of this trial (while on MLN 9708); patients may enroll in transplant and post transplant studies after consolidation 1 treatmentXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drugXx_NEWLINE_xXPatients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy; (Note: patients on the standard therapy arm of another GBM trial that otherwise meet eligibility requirements for this trial remains eligible for cohort 1)Xx_NEWLINE_xXPatients previously treated on clinical trial with reolysinXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunizationXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, =< 30 days prior to registrationXx_NEWLINE_xXParticipation in other clinical trials with the same primary endpointXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.Xx_NEWLINE_xXParticipation in any other clinical trials with other investigational agents not included in this trial ? 21 days prior to registrationXx_NEWLINE_xXPrevious clinical trial enrollment is allowedXx_NEWLINE_xXPatients participating in a clinical trial where prevention of GVHD is the primary endpoint.Xx_NEWLINE_xXEnrollment in a concurrent clinical study.Xx_NEWLINE_xXConcurrent participation in another therapeutic or imaging clinical trial.Xx_NEWLINE_xXConcurrent participation in another therapeutic treatment trialXx_NEWLINE_xXCurrent participation in any other interventional clinical study (except survival follow up).Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomizationXx_NEWLINE_xXPatient is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drugXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participationXx_NEWLINE_xXConcomitant use of herbal medications at least 7 days prior to the first dose of study drug and throughout participation in the trial.Xx_NEWLINE_xXConcurrent use of other investigational drugs or treatment in another clinical trial with a non-FDA-approved medication within the past 4 weeks before start of therapyXx_NEWLINE_xXActively participating in another clinical treatment trialXx_NEWLINE_xXCurrently enrolled in a clinical study.Xx_NEWLINE_xXConcurrent participation in another interventional clinical trial or use of another investigational agent within 30 days of study entry Note: Patients who are participating in non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.Xx_NEWLINE_xXParticipation in another interventional clinical trial unless prior approval has been received from the Chimerix Medical Monitor (or designee).Xx_NEWLINE_xXParticipation in another clinical study involving an investigational product within 1 month before study entry;Xx_NEWLINE_xXPatients must have life-expectancies > 6 months to be included in the trialXx_NEWLINE_xXParticipation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollmentXx_NEWLINE_xXSubject is participating in any other therapeutic clinical study (observational or registry trials are allowed)Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXAre currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.Xx_NEWLINE_xXTreatment with any investigational agent on a different clinical trial within 30 days of enrollmentXx_NEWLINE_xXTreatment with any investigational agent on a different clinical trial within 30 days of lymphodepleting chemotherapyXx_NEWLINE_xXSubjects who have participated in a clinical trial within 30 days of Screening or are scheduled to receive an investigational product.Xx_NEWLINE_xXTreatment with any investigational agent or on an interventional clinical trial within 30 days prior to treatment on protocolXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeks.Xx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional studyXx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXPatients voluntarily participate in the clinical trial, understanding they may withdraw participation at any timeXx_NEWLINE_xXPatients who were enrolled into any other treatment clinical trial and received treatment on that trial within 4 weeks of study treatmentXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the 4 weeks prior to therapy initiationXx_NEWLINE_xXHave participated in a prior oregovomab clinical trial. Prior treatment with Hiltonol® does not exclude a subject from participation.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollmentXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 1 month prior to initiation of therapyXx_NEWLINE_xXConcurrent treatment with other experimental drugs or participation in another clinical trial with any investigational medicinal product (IMP) within ? 5 x the half-life of the IMP prior to day 1 cycle 1 of Minnelide.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 6 monthsXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial within 28 days prior to study entry;Xx_NEWLINE_xXSymptoms of a clinically significant illness that may place the subject at risk by trial participation or influence the outcome of the trial in the four weeks before first treatment and during the trial;Xx_NEWLINE_xXParticipation in the treatment phase of another clinical trial within the four weeks prior to treatment in this clinical trial;Xx_NEWLINE_xXUp to 5 of the 15 patients will be allowed to have had other approved or investigational drugs after prior progression of regorafenib monotherapy; (all patients enrolled in this trial must have had prior progression on regorafenib therapy); this may include TAS102, off-label therapy that may have been prescribed based on tumor genomic profiling or any investigational agents on a clinical trialXx_NEWLINE_xXParticipated within the last 30 days in a clinical trial.Xx_NEWLINE_xXCurrently enrolled in another clinical trial.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXParticipated in a previous clinical trial or used any investigational drugs, biologics, or devices within 90 days prior to study treatment or plans to use any of these during the course of the study.Xx_NEWLINE_xXPatients may not be on a concurrent clinical trial, unless approved by PI.Xx_NEWLINE_xXParticipating in any other clinical trials using an investigational product.Xx_NEWLINE_xXParticipation in a trial of an investigational agent within the prior 30 daysXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 1 monthXx_NEWLINE_xXParticipation in another clinical study with an investigational product administered during the last 28 days.Xx_NEWLINE_xXConcurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 5 half lives of those investigational agents before the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in a different trial that increases a patient’s risk of VTEXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial throughout the duration of this trialXx_NEWLINE_xXTreatment with any investigational agent or on an interventional clinical trial within 30 days prior to registrationXx_NEWLINE_xXRequiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participationXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeks (prior use of bevacizumab in the upfront setting is allowed)Xx_NEWLINE_xXPrevious enrolment in this trialXx_NEWLINE_xXPatients may not be receiving the treatment targeting the activated gene as part of a clinical treatment trial other than the Precision Oncology TrialXx_NEWLINE_xXParticipation in an investigational therapeutic drug trial within 30 days of study entryXx_NEWLINE_xXCurrently enrolled in, or discontinued within the last 14 days from a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this studyXx_NEWLINE_xXPatients who are currently participating in any other clinical trial of an investigational productXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, =< 30 days prior to registration and throughout the duration of this trialXx_NEWLINE_xXTreatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional studyXx_NEWLINE_xXParticipation in another clinical study with an investigational product for cancer during the last 12 monthsXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study, is excludedXx_NEWLINE_xXSimultaneous participation in other therapeutic clinical trials will not be allowedXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 6 months (mo)Xx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional studyXx_NEWLINE_xXConcurrent enrollment in another clinical trial, unless in a follow-up period or it is an observational studyXx_NEWLINE_xXPatients who are currently participating in any other clinical trial of an investigational productXx_NEWLINE_xXSevere active comorbidities which would make the patient an unacceptable candidate for this clinical trial per physician discretionXx_NEWLINE_xXParticipation in another clinical trial with any investigative drug within 30 days prior to study enrolmentXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXEnrolled on another clinical trial testing a novel therapy or drugXx_NEWLINE_xXCurrent or anticipated use of other investigational agents; NOTE the following clarification for this study:\r\n* Prohibited concurrent therapy: \r\n** Participation in clinical trials with other investigational agents, not included in this trial, within 14 days of the start of this trial until 2 weeks after subject has received the last dose of bortezomib for mobilization\r\n** Hypersensitivity to bortezomib, boron or mannitol or G-CSFXx_NEWLINE_xXCurrent or previous treatment with investigational therapy in another therapeutic clinical trial interrupted less than 4 weeks before study treatment initiation.Xx_NEWLINE_xXConcurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional studyXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXCurrent active treatment in another clinical studyXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 3 monthsXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical trialXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical trialXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical trialXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical trialXx_NEWLINE_xXParticipation in other clinical trials involving investigational agents within 21days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXSubjects requiring or using other investigational agents while on treatment in this trial.Xx_NEWLINE_xXSimultaneous participation in other therapeutic clinical trials will be allowedXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) (phases 1-4) within 2 weeks before randomization in the current studyXx_NEWLINE_xXParticipation to a study involving a medical or therapeutic intervention in the last 30 daysXx_NEWLINE_xXPrior participation in this studyXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days prior to start of study treatment and throughout the duration of this trialXx_NEWLINE_xXCurrent treatment on another clinical trialXx_NEWLINE_xXPatients treated on any other therapeutic clinical protocols within 10 days prior to registration or during participation in the studyXx_NEWLINE_xXParticipation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.Xx_NEWLINE_xXCurrently receiving any investigational drug or device in another clinical trial or within 30 days preceding informed consent.Xx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXParticipation in other clinical trials with investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial or throughout the duration of this trialXx_NEWLINE_xXEvidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trialXx_NEWLINE_xXParticipation in other clinical trials with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in a previous clinical trial of enzalutamide or an investigational agent that inhibits the androgen receptor (ARN-509) or androgen synthesisXx_NEWLINE_xXParticipated in a therapeutic clinical study within 3 weeks before study drug treatment, or current participation in other therapeutic investigational procedures.Xx_NEWLINE_xXTreatment with chemotherapy, monoclonal antibodies or biological agents (e.g. lenalidomide) other than the investigational agents during the time of participation in this trialXx_NEWLINE_xXPatients who have not completed standard of care treatment prior to participation in this trial, i.e. surgical procedure and radiation therapy (at least 59 Gy); Note: If tumor is unmethylated, patients are not mandated to have received chemotherapy prior to participation in this trial; however, if tumor is methylated, patients must have received at least one chemotherapy regimen prior to participation in this trialXx_NEWLINE_xXParticipation in another investigational trial concurrently or within 30 daysXx_NEWLINE_xXPatients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the studyXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational therapeutic drug within 1 month prior to dosingXx_NEWLINE_xXParticipation in another clinical trial with drug intervention within 21 days prior to start of cycle 1 and during the studyXx_NEWLINE_xXParticipation in a clinical study involving receipt of an investigational drug during the last 30 days.Xx_NEWLINE_xXPatients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registrationXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registrationXx_NEWLINE_xXPatients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the studyXx_NEWLINE_xXParticipation in another investigational trial within 90 daysXx_NEWLINE_xXParticipation in another clinical trial with drugs received within 3 months prior to dosing (calculated from the previous study's last dosing date).Xx_NEWLINE_xXParticipation in an investigational new drug trial within 28 days prior to initiating treatment on studyXx_NEWLINE_xXHave at least 1 measurable lesion of ? 1.0 cm. Confidential and Proprietary 6 ALT-803 and Pembrolizumab for NSCLC Altor BioScience Clinical Trial Protocol: QUILT-2.023Xx_NEWLINE_xXConcurrent participation in any interventional clinical trial.Xx_NEWLINE_xXCurrently participating in another clinical trial using an investigational study medication, or recent participation in such a trialXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in another interventional clinical trial or treatment with any investigational drug within 4 weeks prior to study entry.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product (IP) during the last 3 weeks before the first day of study treatmentXx_NEWLINE_xXParticipation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.Xx_NEWLINE_xXConcurrent enrollment in another clinical studyXx_NEWLINE_xXUse of GSK2315698 (CPHPC), or participation in a separate clinical trial involving CPHPC within 3 months of screeningXx_NEWLINE_xXConcurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 4 weeks prior to study entry.Xx_NEWLINE_xXConcurrent participation in another therapeutic clinical trialXx_NEWLINE_xXEnrollment in a concomitant clinical studyXx_NEWLINE_xXPlanned concomitant participation in another clinical trial of an experimental agent, vaccine, or device. Concomitant participation in observational studies is acceptable.Xx_NEWLINE_xXParticipation in an investigational trial within 30 days of study entryXx_NEWLINE_xXAre participating or have participated in another clinical trial for the palliation of their targeted bone metastasis tumors in the last 30 daysXx_NEWLINE_xXCurrent treatment in another clinical studyXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation;Xx_NEWLINE_xXAny other investigational treatments within 4 weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trialsXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 3 weeksXx_NEWLINE_xXConcurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this studyXx_NEWLINE_xXCurrent participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable after sponsor approval.Xx_NEWLINE_xXPrevious treatment with crenolanib or prior participation in clinical trial involving crenolanib.Xx_NEWLINE_xXCurrently participating in another clinical trialXx_NEWLINE_xXParticipation in other investigational studies while enrolled on this trial.Xx_NEWLINE_xXPatients with known metastases would be excluded from this clinical trialXx_NEWLINE_xXSystemic anti-cancer therapy or participation in other clinical trials, including those with other investigational agents not included in this trial, ? 28 days of registration and throughout the duration of active treatment in this trialXx_NEWLINE_xXAny other experimental treatment on another clinical trialXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional studyXx_NEWLINE_xXParticipation in any other ongoing ceftolozane/tazobactam trialXx_NEWLINE_xXIs currently participating or has participated in any other any other investigational or therapeutic trial before or after chemoradiation.Xx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial throughout the duration of this trialXx_NEWLINE_xXEnrolled in another clinical trial with a targeted endpoint of treating the patient’s cancer (observational trials are acceptable)Xx_NEWLINE_xXOnly patients with tumors that score positive in the in vitro organoid bio-assay will be enrolled in the clinical trial; patients with tumors that score negative in this bio-assay will be considered screening failures and will not be enrolled in the clinical trialXx_NEWLINE_xXConcurrent participation in a clinical trial which involves another investigational agentXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and within 30 days of any dose of bortezomibXx_NEWLINE_xXParticipation in other investigational studies concurrently if these therapies include a therapeutic interventionXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXSubjects who have recently been enrolled in other experimental clinical trials of\n             investigational agentsXx_NEWLINE_xXParticipation in any other clinical trials with other investigational agents not included in this trial, =< 21 days prior to registrationXx_NEWLINE_xXConcurrent treatment with any other anti-neoplastic drug or concurrent participation in another therapeutic clinical trialXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of the trial and throughout the duration of this trialXx_NEWLINE_xXConcurrent treatment with any other anti-neoplastic drug or concurrent participation in another therapeutic clinical trialXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXConcurrent enrollment in another clinical study, except for non-interventional, observational studiesXx_NEWLINE_xXParticipation in another interventional clinical trial at the time of enrollmentXx_NEWLINE_xXClinical performance status equivalent to ECOG 0-1 at the clinical visit prior to apheresisXx_NEWLINE_xXCurrent treatment on another clinical trial; participation in non-therapeutic clinical trials is permissibleXx_NEWLINE_xXCurrent participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this studyXx_NEWLINE_xXCurrent participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this studyXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXDiagnosed less than 3 years prior to entry on trialXx_NEWLINE_xXParticipation in another clinical trial/investigation within 28 days prior to study drugXx_NEWLINE_xXParticipation in a clinical trial using experimental therapy within the last 4 weeks prior to randomizationXx_NEWLINE_xXParticipation in a clinical trial using immunological experimental therapy (e.g. monoclonal antibodies, cytokines or active cellular immunotherapies) within the last 6 months prior to randomizationXx_NEWLINE_xXHistory of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.Xx_NEWLINE_xXParticipation in another clinical trial within 4 weeksXx_NEWLINE_xXTreatment with any other test drug or participation in another clinical trial within 28 days of enrollment.Xx_NEWLINE_xXSubject is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.Xx_NEWLINE_xXClinical laboratory values:Xx_NEWLINE_xXParticipation in a clinical trial with an investigational therapy within 30 days prior to randomizationXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowedXx_NEWLINE_xXParticipation in another clinical trial with any investigational drug within 30 days prior to study entry.Xx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXConcurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to randomization.Xx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional studyXx_NEWLINE_xXCurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXMajor surgical intervention or participation in a therapeutic clinical trial within 28 days from Day 1 of the first dose of MSC2363318AXx_NEWLINE_xXConcurrent participation in an investigational drug trial with therapeutic intentXx_NEWLINE_xXParticipation in another interventional clinical trial within the past 30 days (participation in observational studies is permitted)Xx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXPatients who currently are participating in other phase III therapeutic clinical trials and/or who have participated in other phase III therapeutic clinical trials in the previous 30 daysXx_NEWLINE_xXParticipation in concurrent clinical trials evaluating treatment intervention(s)Xx_NEWLINE_xXCurrent participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this studyXx_NEWLINE_xXConcurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXPrior treatment in any other clinical trial involving another investigational agent within 4 weeks prior to Day -31 of the study; resolution of respective adverse event to Grade 1 or lower should have occurredXx_NEWLINE_xXCurrently enrolled in another clinical trial (exclude non-cancer treatment trial) or received an investigational agent within 4 weeks of study initiationXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) study.Xx_NEWLINE_xXPrevious participation in tremelimumab or ipilimumab clinical trial or prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonistXx_NEWLINE_xXAre currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.Xx_NEWLINE_xXParticipation in any other clinical trialXx_NEWLINE_xXAre currently enrolled in another clinical trial.Xx_NEWLINE_xXHave discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.Xx_NEWLINE_xXSystemic treatment on any investigational clinical trial within 28 days prior to registration.Xx_NEWLINE_xXAre currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this studyXx_NEWLINE_xXUse of any investigational drug within 4 weeks before start of trial treatment or concomitantly with this trial.Xx_NEWLINE_xXPatients (at institutions listed) must be offered the opportunity to participate in the optional S1406 Co-Clinical PDX Model trial; participating patients must have a fresh tissue biopsy for the Co-Clinical PDX Model Trial completed within 7 days of Step 2 RandomizationXx_NEWLINE_xXParticipation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within 2 weeks prior to randomizationXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXPatients must not be participating in any other therapeutic clinical trial or taking any other experimental medications within 14 days prior to registrationXx_NEWLINE_xXConcurrent anti-cancer treatment in another investigational trialXx_NEWLINE_xXCurrent participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollmentXx_NEWLINE_xXParticipation in a therapeutic research study or receipt of an investigational drug within 4 weeks of leukapheresisXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowedXx_NEWLINE_xXPrior treatment in clinical trial UTX-TGR-304Xx_NEWLINE_xXSystemic therapy with immunosuppressive agents within 7 days before the start of trial treatment; or use of any investigational drug within 28 days before the start of trial treatmentXx_NEWLINE_xXEvidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trialXx_NEWLINE_xXClinical laboratory values:Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXTreatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 21 daysXx_NEWLINE_xXParticipation in another clinical study with receipt of an investigational product during the last 4 weeksXx_NEWLINE_xXParticipation in a clinical trial involving an investigational drug within 30 days of study startXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial and throughout the duration of this trial; within at least 5 half-lives of previous therapy for smoldering myeloma at start of this trialXx_NEWLINE_xXParticipation in any other clinical investigation within 4 weeks of receiving the first dose of study drugXx_NEWLINE_xXTreatment on another therapeutic clinical trial within 4 weeks of enrollment in this trialXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), and imaging trials, are allowedXx_NEWLINE_xXConcurrent enrollment in another therapeutic clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)Xx_NEWLINE_xXThe participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.Xx_NEWLINE_xXParticipation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.Xx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXPrior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study.Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollmentXx_NEWLINE_xXPatients who are currently enrolled on another clinical trialXx_NEWLINE_xXTreatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib) or other than the investigational agents during the time of participation in this trialXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional studyXx_NEWLINE_xXSimultaneous participation in other therapeutic clinical trials will not be allowedXx_NEWLINE_xXCurrent, or recent (within 30 days, or 5 half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.Xx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial (for all other standard therapies, no treatment within 14 days of the start of this trial)Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollmentXx_NEWLINE_xXAre currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this studyXx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXConcurrent investigational therapy given to treat cancer or concurrent participation in another clinical trial involving anti-cancer investigational drug.Xx_NEWLINE_xXCurrent enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reasonXx_NEWLINE_xXPrior participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless the treatment was placebo)Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollmentXx_NEWLINE_xXConcurrent anti-cancer treatment in another investigational trialXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) within 4 weeks prior to study participation and/or during study participation.Xx_NEWLINE_xXPART A: Able (physically and financially) to travel to University of Colorado for clinical trial treatmentXx_NEWLINE_xXEnrolled on another clinical trial testing a novel therapy or drugXx_NEWLINE_xXPatients receiving or participating on any other experimental agents/clinical trials are not eligible for participationXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-treatment (i.e. quality of life) are allowedXx_NEWLINE_xXPrior randomization into this clinical study.Xx_NEWLINE_xXParticipation in concurrent investigational studiesXx_NEWLINE_xXParticipation in another clinical trial unless approved by the lead principal investigatorXx_NEWLINE_xXPatients who have participated in other interventional (treatment-related) clinical trials within 30 days of enrollment are excludedXx_NEWLINE_xXPatients with nervous system tumors associated with NF2 (e.g., schwannomas, meningiomas, ependymomas, or gliomas) will not be excluded from this clinical trial unless (in the opinion of the investigator) these tumors are growing and are likely to require treatment during the clinical trialXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of bortezomib treatment on day +7; exceptions require approval of the study PI; and notifying Millennium Pharmaceuticals Incorporated (Inc.) within 72 hoursXx_NEWLINE_xXCurrently have no clinical evidence of diseaseXx_NEWLINE_xXParticipation in an investigational therapeutic drug trial within 30 days of study entryXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXAre currently enrolled or discontinued less than 14 days from another clinical trialXx_NEWLINE_xXParticipation in another investigational drug clinical trialXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowedXx_NEWLINE_xXCurrent enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reasonXx_NEWLINE_xXPatients who have participated in any therapeutic clinical study/received any investigational agent within the last 30 days are excluded from participation in this trial.Xx_NEWLINE_xXParticipation in another investigational drug clinical trial.Xx_NEWLINE_xXParticipation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during studyXx_NEWLINE_xXE 09. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.Xx_NEWLINE_xXAre currently enrolled in, or discontinued within the last 28 days from a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this studyXx_NEWLINE_xXCurrent treatment on another clinical trialXx_NEWLINE_xXEXPANSION COHORT ONLY: Current treatment on another clinical trialXx_NEWLINE_xXconcurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 14 daysXx_NEWLINE_xXParticipation in another clinical study with receipt of an investigational product during the last 4 weeksXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the previous 4 weeksXx_NEWLINE_xXCurrent participation in other clinical studyXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless in a follow-up period or it is an observational studyXx_NEWLINE_xXPatient participating in another clinical trial or receiving an investigational drugXx_NEWLINE_xXParticipation in any clinical study or having taken any investigational therapy within 28 days.Xx_NEWLINE_xXPatients who were assigned to an axitinib containing treatment arm in a previous clinical trialXx_NEWLINE_xXcurrent participation in other clinical studyXx_NEWLINE_xXParticipation in a previous vaccine trialXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) (Phases 1-4) within 4 weeks of registering for the current study and/or during study participation.Xx_NEWLINE_xXConcurrent participation in another therapeutic clinical trialXx_NEWLINE_xXParticipation in a clinical trial of an investigational device or drug within 4 weeks of study entry.Xx_NEWLINE_xXConcurrent participation in another therapeutic clinical trial;Xx_NEWLINE_xXConcurrent participation or participation within the last 30 days prior to enrollment in any clinical trial with an investigational medicinal drug/chemotherapeutic or biologic or medical product.Xx_NEWLINE_xXConcurrent participation in another therapeutic clinical trialXx_NEWLINE_xXReceived last dose of study drug on another therapeutic clinical trial within 30 days prior to randomizationXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.Xx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial throughout the duration of this trialXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 4 weeksXx_NEWLINE_xXParticipation in another clinical trial or treatment with any investigational drug (excluding anticancer treatments) within 30 days of study startXx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xXTreatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trialXx_NEWLINE_xXSubject is enrolled in any other clinical protocol or investigational trial with an interventional agent or assessments that may interfere with study procedures.Xx_NEWLINE_xXCurrent participation in another drug trialXx_NEWLINE_xXConcurrent use of any other investigational agents on a clinical trialXx_NEWLINE_xXParticipation in other clinical trials with other investigational agents not included in this trial, within 21days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in clinical drug trials within 4 weeksXx_NEWLINE_xXPatients must be considered good candidates for a phase 1 trial and the treating physician must intend to enroll the patient on a phase 1 clinical protocol, if possible; patients are not required to have progressed on their last line of therapy prior to enrollment\r\n* Other clinical trials are also acceptable; for example, an applicable phase 2 or phase 3 trial may exist for which the patient would be eligible and for which available information (inclusive of next generation sequencing [NGS]) would be relevant to such enrollment; regardless, the pertinent point is that it is the intent of the physician to use NGS data, to the degree possible, to select appropriate therapy, when selecting patients for this trialXx_NEWLINE_xXReceived last dose of study drug on another therapeutic clinical trial within 30 days prior to enrollmentXx_NEWLINE_xXParticipation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXPatient should not be part of another trial testing other investigational agents or devicesXx_NEWLINE_xXParticipation in a therapeutic research trial within the past three monthsXx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials, surgical clinical trials, or non-treatment trials, e.g. quality of life (QOL), are allowedXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to day 1 of the study.Xx_NEWLINE_xXPatient is enrolled in any other therapeutic clinical protocol or investigational trialXx_NEWLINE_xXPatients enrolled must, in the Investigator's judgment, be healthy enough to stay on the clinical trial for three months.Xx_NEWLINE_xXActively participating in another therapeutic clinical trialXx_NEWLINE_xXPatient is enrolled in any other therapeutic clinical protocol or investigational trialXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXAny previous treatment with study drug (RO5185426) or participation in a clinical trial that includes RO5185426Xx_NEWLINE_xXParticipation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1)Xx_NEWLINE_xXCurrently participating in any other interventional clinical studyXx_NEWLINE_xXHas completed the CS35 trial.Xx_NEWLINE_xXHas been withdrawn from the CS35 trial.Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXParticipation in a therapeutic research study or receipt of an investigational drug within 30 days of T-cell infusionXx_NEWLINE_xXSimultaneous participation in other therapeutic clinical trials will not be allowedXx_NEWLINE_xXTreatment with chemotherapy or monoclonal antibody during the time of participation in this trialXx_NEWLINE_xXUse of an investigational agent or participation in another clinical trial within 4 weeks prior to randomizationXx_NEWLINE_xXIs concurrently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo.Xx_NEWLINE_xXConcurrent participation in another therapeutic treatment trial.Xx_NEWLINE_xXPrevious participation in a clinical study of KevetrinXx_NEWLINE_xXParticipation in a trial of an investigational agent within the prior 30 daysXx_NEWLINE_xXConcurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXReceipt of investigational therapy in a clinical trial setting within 30 days of enrollment;Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment; the following exceptions are allowed:\r\n* Unapproved/ experimental TKIs discontinued 14 days prior to cycle 1, day 1Xx_NEWLINE_xXClinical evidence of cirrhosisXx_NEWLINE_xXParticipation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.Xx_NEWLINE_xXCurrently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.Xx_NEWLINE_xXThe patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to Day 1 of CycleXx_NEWLINE_xXParticipation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to study entryXx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXConcurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional studyXx_NEWLINE_xXWas enrolled on the Phase 1 clinical trial ONT-10-001 and:Xx_NEWLINE_xXTreatment with other investigational agents, chemotherapy, or immunotherapy within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1Xx_NEWLINE_xXCurrent enrollment in another clinical study.Xx_NEWLINE_xXParticipation in another clinical study with an investigational drug within 30 days of Screening.Xx_NEWLINE_xXParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXParticipation in another clinical trial in which they received active therapy within 4 weeks prior to the first dose of study drug.Xx_NEWLINE_xXPatient has not previously participated in any clinical trial of iniparib.Xx_NEWLINE_xXConcurrent enrollment in another investigational clinical studyXx_NEWLINE_xXPrior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol).Xx_NEWLINE_xXAre currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.Xx_NEWLINE_xXCurrent or previous participation in the treatment phase of another interventional clinical study within 4 weeks prior to randomization. Patients may continue in the follow-up phase of another interventional clinical study, but may not have undergone any treatment on the other study within 4 weeks prior to randomization.Xx_NEWLINE_xXParticipation in another clinical trial or use of any investigational drug within 30 days prior to study entryXx_NEWLINE_xXcurrent treatment in another clinical trialXx_NEWLINE_xXConcurrent treatment with an investigational agent or participation in another treatment clinical trial;Xx_NEWLINE_xXTreatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trialXx_NEWLINE_xXParticipation in a Phase I lapatinib trial that has met its study objectives.Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrollmentXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 14 daysXx_NEWLINE_xXParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drugXx_NEWLINE_xXPatients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the studyXx_NEWLINE_xXPatients who previously participated in or are currently participating in another intervention clinical trial designed to improve adherenceXx_NEWLINE_xXEnrollment in a Phase I trialXx_NEWLINE_xXPatients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its componentsXx_NEWLINE_xXEnrolled on a phase I trialXx_NEWLINE_xXAre participating or have participated in another clinical trial in the last 30 daysXx_NEWLINE_xXSubject must currently be participating in an ibrutinib clinical trial, deriving clinical benefit from treatment with ibrutinib in the opinion of the treating physician and do not have access to commercial ibrutinib within their region.Xx_NEWLINE_xXConcurrent treatment on another clinical trial; supportive care trials or non-therapeutic trials (i.e. quality of life) are allowedXx_NEWLINE_xXParticipation in any other clinical study within the last 4 weeks prior to the start of the studyXx_NEWLINE_xXInvestigational treatment or clinical trial within 4 weeks.Xx_NEWLINE_xXActive treatment on another clinical trial.Xx_NEWLINE_xXPatients whose participation in this trial would require exclusion from participation in another clinical research trial related to the patient's malignant diagnosisXx_NEWLINE_xXEvidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trialXx_NEWLINE_xXPatients currently enrolled onto therapeutic cancer clinical trial(s) involving non-standard cancer drugsXx_NEWLINE_xXEnrolled on a therapeutic or supportive care clinical trialXx_NEWLINE_xXCurrent participation in a trial with another investigational agent, unless co-enrollment is approved by the principal investigators (PIs) of both studiesXx_NEWLINE_xXParticipation in another investigational trial concurrently or within 30 daysXx_NEWLINE_xXConcomitant participation in any other investigational treatment study; simultaneous participation in non-therapeutic or observational studies will not be an exclusion criterionXx_NEWLINE_xXThere is evidence of the disease at the time of entry into the trialXx_NEWLINE_xXConditioning regimens 30 days (d) prior to trial participation and up to d28 post-HCTXx_NEWLINE_xXOther investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibitedXx_NEWLINE_xXConcurrent participation in another chemoprevention trialXx_NEWLINE_xXOther investigational product — concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibitedXx_NEWLINE_xXPatients previously enrolled on this trial are ineligibleXx_NEWLINE_xXTRIAL SUBJECTS:Xx_NEWLINE_xXPrevious participation in GCRAXx_NEWLINE_xXParticipation in another clinical trial or use of another investigational agent within 30 days of study entryXx_NEWLINE_xXParticipants will have no previous history of clinical trial research participationXx_NEWLINE_xXEnrollment in another investigational drug trialXx_NEWLINE_xXPatients must be enrolled in a Phase 1 clinical trial and be within 2 weeks of starting the experimental therapy or interventionXx_NEWLINE_xXPrevious participation in randomization in this trialXx_NEWLINE_xXApproval for participation in the trial by attending physicianXx_NEWLINE_xXSubject has previously participated in any clinical trial with the investigational device.Xx_NEWLINE_xXSubject currently enrolled in any other clinical investigation or who has participated in any clinical investigation in the 30 days prior to starting this study.Xx_NEWLINE_xXEnrolled in a clinical trial involving an investigational product or nonapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study.Xx_NEWLINE_xXDiscontinued from study treatment from another clinical trial within 28 days prior to randomization.Xx_NEWLINE_xXPatients who are enrolled in another symptom management trial or receiving active treatment under another clinical trialXx_NEWLINE_xXNote: Patients who enroll in hospice during the trial will have the option of continuing trial participationXx_NEWLINE_xXPatients who are enrolled in other symptom management clinical trialsXx_NEWLINE_xXPatients may concurrently participate in other therapeutic clinical trialsXx_NEWLINE_xXConcurrent participation in other investigational studies allowedXx_NEWLINE_xXParticipation in a therapeutic clinical trialXx_NEWLINE_xXPatients are permitted to participate in other clinical trials while participating in this trialXx_NEWLINE_xXCaregivers will be eligible for enrollment if they identify as the person who is the caregiver of a patient enrolled in a phase I oncology clinical trialXx_NEWLINE_xXCurrent daily application of a prescribed topical product to the skin within the RT area for an unrelated skin condition that cannot be discontinued during the participation in this clinical trialXx_NEWLINE_xXConcurrent participation in a clinical trial which involves another investigational agentXx_NEWLINE_xXParticipants must not have been asked previously to participate in another therapeutic cancer clinical trialXx_NEWLINE_xXParticipants must not have already made a decision to participate in the phase II or III therapeutic clinical trial for which they were informed of their eligibilityXx_NEWLINE_xXParticipation of patients on other clinical trial protocols permitted, if not prohibited by trial guidelinesXx_NEWLINE_xXPrevious participation in this studyXx_NEWLINE_xXCLINICAL PROCOTOL USED AS REFERENCE FOR THIS STUDY:Xx_NEWLINE_xXRANDOMIZED CONTROL TRIAL:Xx_NEWLINE_xXIndividuals must not currently be participating in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only; patients must also agree not to join such a trial while participating in this studyXx_NEWLINE_xXParticipation in another clinical trial involving an investigational product within 30 days prior to screening; orXx_NEWLINE_xXParticipation in a clinical trial evaluating another preventative strategy for chronic graft-versus-host disease (GVHD), or ongoing participation in a clinical trial for therapy of acute GVHD; prior completion of experimental therapy for acute GVHD is permissible if the experimental agent was used > 30 days prior to enrollmentXx_NEWLINE_xXRECIPIENT: Other investigational product – concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibitedXx_NEWLINE_xXPrevious participation in this trial. Participation is defined as screening. Re-screening is not allowed.Xx_NEWLINE_xXIndividuals enrolled in or who plan to enroll in a clinical intervention trial; there must be a 30-day period between completing a previous study and enrolling in this study; the principal investigator will have the option to consider an exception for patients on drugs of interest for the purpose of this studyXx_NEWLINE_xXPrevious participation in any clinical trial involving rolapitantXx_NEWLINE_xXParticipation in a clinical trial evaluating another preventative or treatment strategy for chronic GVHD or ongoing participation in a clinical trial for therapy of acute GVHD; prior completion of experimental therapy for acute GVHD is permissible if the experimental agent was used > 30 days prior to enrollmentXx_NEWLINE_xXPatient’s deemed otherwise clinically unfit for clinical trial per investigator’s discretionXx_NEWLINE_xXAre currently enrolled in a physical activity and/or dietary clinical trialXx_NEWLINE_xXMust not participate in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only. Participants must also agree not to join such a trial while participating in this study.Xx_NEWLINE_xXConcurrent participation in another clinical trialXx_NEWLINE_xXPatients who have participated in a clinical trial of an investigational drug within 12 months prior to enrollmentXx_NEWLINE_xXParticipation in a trial of an investigational medicinal product within the previous 28 daysXx_NEWLINE_xXPatients enrolled on another investigational trial for oral mucositis preventionXx_NEWLINE_xXThe use of any investigational agent within 30 days preceding the first dose of the study vaccine or subsequent participation in another clinical trial at any time during the study period, in which the subject will be exposed to an investigational productXx_NEWLINE_xXCurrent participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 14 daysXx_NEWLINE_xXClinical diagnosis of asthmaXx_NEWLINE_xXSubject is currently participating on a separate otoprotection clinical study.Xx_NEWLINE_xXHave participated in any clinical trial in the previous 30 days.Xx_NEWLINE_xXReceiving another investigational agent on a clinical trial that prohibits participation in other studies of investigational agentsXx_NEWLINE_xXPatients receiving active therapy on an investigational trial at the time of enrollment should consult with the study chair regarding potential interactions with other study agents; patients who are enrolled in a clinical trial but are off-therapy and in follow up are eligibleXx_NEWLINE_xXParticipation in another clinical trial involving an investigational agent within 4 weeks of enrollmentXx_NEWLINE_xXCurrent enrollment in a therapeutic clinical trialXx_NEWLINE_xXNormal tone on clinical examXx_NEWLINE_xXClinical instabilityXx_NEWLINE_xXThe participant will be excluded from participation in another clinical research trial (i.e., a trial in which an agent is actively administered to the study subject), while being imaged (on active treatment) on this protocolXx_NEWLINE_xXParticipation in another clinical study in the month preceding this studyXx_NEWLINE_xXParticipation in other clinical study within the last 30 daysXx_NEWLINE_xXPatient has participated in a clinical study of an investigational drug or device within 3 months prior to screening CDU that may have an impact on clinical outcomes; and,Xx_NEWLINE_xXEnrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that studyXx_NEWLINE_xXIntention to enroll in a blinded therapeutic clinical trialXx_NEWLINE_xXPatient is participating in a clinical trial of another investigational drug or deviceXx_NEWLINE_xXParticipation in another investigational drug trial either concurrently or 30 days prior to surgeryXx_NEWLINE_xXSubject must have a life expectancy that exceeds the duration of the clinical trialXx_NEWLINE_xXParticipant in a clinical trial involving an investigational drug within the past 30 daysXx_NEWLINE_xXHaving received an investigational drug in an investigational drug trial within the last 30 days before randomization for this clinical trial. Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted. Part B, Exclusion criteria: All exclusion criteria as for Part A, except for inclusion criteria 1 and 12 which are replaced by:Xx_NEWLINE_xXKnown intolerance to pritelivir or any of the excipients and 12. Having received an investigational drug in an investigational drug trial within the last 30 days before Day 1 for this clinical trial (except for subjects entering Part B who have previously received foscarnet treatment in Part A of this trial). Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted.Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 21 daysXx_NEWLINE_xXPatient has completed participation in another clinical study involving administration of an investigational agent in the preceding 4 weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator:Xx_NEWLINE_xXPatient already included in this trialXx_NEWLINE_xXPatient included in another clinical trial involving an IMP within 30 days before the first investigational contrast agent injection.Xx_NEWLINE_xXParticipating in a concurrent clinical trial or has participated in another clinical trial with an investigational compound within the past 30 daysXx_NEWLINE_xXTreatment with any experimental therapy within 30 days prior to enrollment or current participation in any other interventional clinical studyXx_NEWLINE_xXParticipation in other clinical trials utilizing other therapeutic investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXBe scheduled to receive at least 6 weeks (i.e. at least 2 cycles) of oral or intravenous (IV) chemotherapy during the study intervention period; therapeutic clinical trial participants are allowedXx_NEWLINE_xXPatients must not be participating or plan to participate in other clinical trials that involve investigational systemic cancer treatments or investigational uses of CSF during their first 6 months after registrationXx_NEWLINE_xXPatients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed; patients may be enrolled to other clinical trials after completing all of the baseline interventions and measuresXx_NEWLINE_xXHave not participated in a clinical trial beforeXx_NEWLINE_xXParticipation in more than 3 research studies in the past 6 months. Participation in a smoking study in the past 6 months. Participation in a study which involved medication within the last monthXx_NEWLINE_xXPatient is participating in a clinical trial of another investigational drug or deviceXx_NEWLINE_xXKnown Stage IV ovarian cancer with brain metastases 14. Received an investigational agent in another clinical trial within 30 days prior to surgery 15. Known sensitivity to fluorescent lightXx_NEWLINE_xXCurrent or pending participation in a clinical trial examining therapy for the\n             treatment of any cancer (including unresectable or metastatic melanoma)Xx_NEWLINE_xXInclusion:\n\n        A parent trial must :\n\n          -  have a coordinating Center willing to allow their Clinical Sites to participate;\n\n          -  be studying be studying a condition that requires community or health system physician\n             referral\n\n          -  be studying an intervention where the recruitment approach cannot be made directly to\n             minority community members\n\n          -  need to increase recruitment of racially/ethnically diverse participants* to the trial\n             as demonstrated by current trial progress or historical data from other trials in the\n             same disease;\n\n          -  be a Phase II or Phase III trial\n\n          -  be conducted in at least six multiple sites;\n\n          -  expect each Clinical Site to recruit at least 10 participants;\n\n          -  be funded by a sponsor (NIH or pharmaceutical company or other) that has a strong\n             commitment to recruiting racially/ethnically diverse subjects;\n\n          -  be willing to have investigators and coordinators attend a special training meeting\n             (at RECRUIT expense);\n\n          -  require randomization to intervention or control (could be best medical care or active\n             control or placebo or other type of control);\n\n          -  provide transportation costs for trial participants who need assistance in getting to\n             trial sites or use some RECRUIT reimbursement for this purpose.\n\n        The clinical site must\n\n          -  be a funded Clinical Site in the parent trial;\n\n          -  be located in an area where at least 20% of the population within 30 miles in the age\n             group under study in the parent trial are from diverse populations.\n\n        Exclusion Criteria:\n\n          -  site does not agree to be randomized;\n\n          -  investigator or coordinator is under 18 years of age.Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolmentXx_NEWLINE_xXCurrent treatment on another therapeutic clinical trialXx_NEWLINE_xX